Tremtelectogene empogeditemcel

曲替基杰干赛

Report date: 2025/07/30 20:01:17

Base Information

Drug NameTremtelectogene empogeditemcel

Drug Alias Nametrem-celan allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product, lacking the CD33 proteinVOR-33

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy +[4]

Mechanisms of ActionStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesVor Biopharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesVor Biopharma Inc

Active IndicationsN/A

Inactive IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A